X
<

Who's Watching Alexion Now?

PART:
1 2 3 4
Part 2
Who's Watching Alexion Now? PART 2 OF 4

How Is Alexion Pharmaceuticals Positioned after 1H17?

Alexion’s revenue trends

In 2Q17, Alexion Pharmaceuticals (ALXN) generated revenues of ~$912 million, which was ~21% higher YoY (year-over-year) and ~5% higher QoQ (quarter-over-quarter). In 1H17, Alexion reported revenues of ~$1.78 billion, compared with $1.45 billion in 1H16.

In 1H17, Alexion reported net income of ~$335 million, compared with $212 million in 1H16. In 2Q17, Alexion generated net income of ~$165 million, compared with $120 million in 2Q16. Soliris and Strensiq pushed revenue growth in 2Q17, rising ~16% and ~84%, respectively, YoY.

How Is Alexion Pharmaceuticals Positioned after 1H17?

Interested in ALXN? Don't miss the next report.

Receive e-mail alerts for new research on ALXN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 2Q17, ALXN reported diluted earnings per common share of $0.73, compared with $0.53 in 2Q16. In 1H17, it reported diluted earnings per common share of $1.49, compared with $0.94 in 1H16.

2Q17 and 1H17 expenses

In 2Q17, Alexion reported a cost of sales of $84 million, compared with $60 million in 2Q16. It reported R&D (research and development), and SG&A (selling, general, and administrative) expenses of ~$199 million and $265 million in 2Q17, respectively, compared with $180 million and $232 million, respectively, in 2Q16.

In 1H17, ALXN reported a cost of sales, R&D expenses, and SG&A expenses of ~$153 million, ~$418 million, and ~$527 million, respectively, compared with $119 million, $356 million, and $465 million, respectively, in 1H16.

Kanuma revenue trends

In 2Q17, ALXN’s Kanuma generated revenues of ~$15 million, compared with $7 million in 2Q16. In 2Q17, Kanuma rose ~25% QoQ.

Alexion’s peers in the rare disease drugs market include Vertex Pharmaceuticals (VRTX), Biogen (BIIB), BioMarin Pharmaceuticals (BMRN), and Sanofi through its subsidiaries, Genzyme and Amgen.

Notably, the iShares Nasdaq Biotechnology ETF (IBB) has ~3.96% of its total portfolio holdings in ALXN.

X

Please select a profession that best describes you: